ClinicalTrials.gg
RecruitingNCT07137104Updated Sep 29, 2026

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease

A Phase 1/2 interventional study of HeXell-2020 in Coronary Artery Disease, sponsored by Hexun Biosciences Co., LTD.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Hexun Biosciences Co., LTD. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Sep 29, 2026Now RecruitingFirst site in Taiwan+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Coronary Artery Disease with a site in Taiwan — 12 open to participants now, 16 under way, 2 of them phase 3. Coronary Artery Disease · Taiwan.

Planned enrollment
47th of 51
39 · median 172
Started
2026
with 2 others
Phase 1/2
Only one
of the 68
Primary completion
2028-12
later than 9 of 15 live
Registered
65th of 68
by date

Among the 68 studies in Coronary Artery Disease with a site in Taiwan, this one is the 47th largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 9 of the 15 other live ones, and was the 65th registered.

Coronary Artery Disease

4,862 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 68 studies in Coronary Artery Disease with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Coronary Artery Disease with a site in Taiwan, or all of them as a file.
02

Study summary

This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.

Read the detailed description

Coronary artery disease (CAD) is the most common form of heart disease and a leading cause of mortality worldwide. It is a manifestation of myocardial ischemia, a condition resulting from insufficient blood flow to the myocardial tissue. CAD occurs when the coronary arteries become progressively narrowed and stiffened due to atherosclerosis-the accumulation of cholesterol, lipids, and plaque along the inner arterial walls. Narrowed blood vessels and increased shear stress may contribute to plaque destabilization, vessel outward remodeling, as well as increased pro-inflammatory cytokines production, leading to advanced atherosclerosis. As the disease advances, this narrowing impairs coronary blood flow, causing permanent heart damage. Over time, CAD can progressively weaken the heart muscle, contributing to heart failure.

Mesenchymal stem cells (MSC) become a potential therapeutic tool for treating cardiovascular diseases due to their capabilities in tissue repair, anti-oxidation, immune-modulation and anti-inflammatory. Intravenous infusion of HeXell-2020, the allogenic umbilical cord MSC, in an atherosclerotic rat model improved blood glucose tolerance, LDL cholesterol levels, and the severity of aortic arch stenosis. Additionally, results further demonstrated significant improvement in atherosclerotic lesions caused by fat deposition at the aortic arch and descending aorta after the treatment. Although the mode of actions of MSCs in CADs have not been fully elucidated, these nonclinical results, together with the established immunomodulatory and anti-inflammatory effects of MSCs, are supportive for the rationale of HeXell-2020 in treating patients with CAD.

This study is composed of two phases, Phase I and Phase IIa. In Phase I, two cohorts were designed following traditional 3+3 scheme to define recommended phae 2 dose (RP2D). In Phase IIa, 22 evaluable subjects are estimated. Safety and efficacy will be evaluated through follow-up visit over one year.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • HeXell-2020
  • Coronary Artery Disease (CAD)
  • Mesenchymal Stem Cells (MSC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who is able to understand the nature of this study and accepts to enter the study by signing written
  2. Male or female who are aged between 18 and 75 years old on date of consent
  3. Patient without LV thrombus or ventricular aneurysm documented by echocardiography at screening
  4. Patient having a diagnosis of CAD caused by ≥ 50% stenosis of at least 1 major or larger epicardial coronary artery (target vessel ≥ 2 mm in diameter without in-stent restenosis) documented by imaging studies within 12 months prior to the date of dosing. If the stenosis results are derived from CCTA, the examination time of CCTA should be at least 6 months prior to screening.
  5. Patient with Canadian Cardiovascular Society (CCS) Class I, II, or III angina pectoris and received optimal, stable, medical therapy (e.g., anticoagulants therapy, β-blockers, calcium channel blockers, nitrates, ranolazine) per country specific treatment guidelines for at least 4 weeks prior to the date of screening, if prescribed
  6. Patients with stable hemodynamic parameters and adequate pulmonary function, defined as systolic pressure ≥ 90 mmHg and \< 150 mmHg, and heart rate > 50/min and \<110/min on at least 2 consecutive readings, at screening and baseline (before dosing)
  7. Patient's medical history shows no history of organ or cell transplant rejection, or suspected to HeXell-2020 including the components (penicillin and streptomycin).
  8. Female subjects show negative pregnancy test results within 30 days prior to the first study treatment.
  9. All male patients and female patients with (between puberty and 2 years after menopause) should use at least any one of the appropriate methods shown below, during dosing and for at least 4 weeks after stopping study treatment.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.
    4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3):

    d.1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. Please refer to 8.2 Prohibited Treatments for detailed information.

    d.2. Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps).

Exclusion criteria

Exclusion Criteria:

  1. Subject had participated in drug trials and took any investigational drugs within 28 days prior to the first treatment.
  2. Patient is schedule to [or has received within 180 days prior to Screening Visit] undergo the following coronary revascularization throughout the study period:

    • Coronary artery bypass grafting (CABG)
    • Valve repair/replacement
    • Cardiac resynchronization therapy (CRT) device
  3. Patient is scheduled to undergo percutaneous coronary intervention (PCI) during the trial before screening.
  4. Patient with high-risk or unstable acute coronary syndrome (e.g., myocardial infarction), major cardiovascular surgery (e.g., coronary valve replacement, or aortic aneurysm surgery), stroke, (TIA), carotid surgery, pulmonary embolism, or deep venous thrombosis in past 90 days prior to the date of screening
  5. Patient with evidence of medical condition as follows,

    • Acute cardiac decompensation
    • Congenital heart disease
    • Significantly uncorrected valvular heart disease
    • Malignant arrhythmia in the absence of a defibrillator
    • Severe pulmonary disease
    • Essential thrombocytosis
    • Anti-phospholipid syndrome
    • Other hypercoagulable disorders (e.g., disseminated intravascular coagulation, Factor V Leiden)
  6. Patient with poorly controlled diabetes mellitus ( >8%) or a known history or present evidence of conditions that may affect study assessments (e.g., currently receiving chemotherapeutic or agents, or have received prior radiation therapy to the chest)
  7. Patient carry history of of any organ system (other than curatively treated localized basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or superficial bladder cancer) within 5 years prior to study entry.
  8. Subject had a history of drug abuse or alcohol abuse according to the 5th edition (DSM-5) criteria.
  9. Evidence of inadequate hematopoietic, hepatic, and renal function as determined by any one of the following laboratory requirements:

    • \<8.5 mg/dL
    • Estimated (eGFR) \<45 mL/min/1.73 m2 as calculated by the Modified in Diet in Renal Disease (MDRD) formula or requiring dialysis prior to study dosing.
    • Total >2× (ULN)
    • (ALT) >3× ULN
  10. Patient with , active , or active infections
  11. Subject who is pregnant or lactating
  12. Subject with underlying medical, mental or psychological conditions that would impair the treatment compliance, unable to undergo study-required tests/scans for any reason, or in the opinion of the investigator would not permit to participate in the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Treatment Cohort

    Phase 1 :single arm. two cohort. cohort 1: HeXell-2020 will be administered by intravenous once every two weeks, and a total of 3 doses. cohort 2: HeXell-2020 will be administered by intravenous once every two weeks, and a total of 6 doses. Phase 2a: Single arm.

    Drug: HeXell-2020

Interventions

  • DrugHeXell-2020

    Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose. Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose. Phase IIa: RP2D from phase I.

06

What researchers measure

Primary outcomes

  1. Incidence of TEAE, SAE and SUSAR over the study

    To evaluate the number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), suspected and unexpected serious adverse reactions (SUSARs) over the study period,

    Time frame: Within the first year after cell transplantaion

  2. To determine the recommended phase II dose (RP2D) in Phase I study

    To determination RP2D, number and proportion of subjects having experienced DLTs will be presented and the RP2D should be determined on the indicated dose at which ≤ 1 patient experiences DLT out of 6 patients who have been DLT evaluated.

    Time frame: Within the first year after cell transplantaion

  3. Change in myocardial perfusion defect severity under the rest acquisition and pharmacological stress of dipyridamole in Phase IIa study

    Measured by SPECT with thallium-201 from baseline. The SRS, SSS and SDS are three variables used to measure cardiac perfusion and ischemia.

    Time frame: Before first dosing and at 12 months post cell transplantaion

Secondary outcomes

  1. Time to the first occurrence of major adverse cardiovascular events (MACEs)

    Including AMI, stroke, cardiovascular mortality, and hospitalization for unstable angina or revascularization procedures, from the date of the first treatment will be analyzed by Kaplan-Meier method.

    Time frame: From the date of the first treatment until the first occurrence of MACE, death, or study cut-off point, unless the subject has withdrawn consent for all contacts or is loss of follow-up, whichever came first, assessed up to 24 months.

  2. Change in the evaluation result of CCTA from baseline

    The stenosis percent of the different coronary segments, using the 17-segment model.

    Time frame: Before first dosing and at 3, 6 months post cell transplantation

  3. Change from baseline in echocardiographic measures.

    Ventricular remodeling: including LVEF in percentage, global longitudinal strain (GLS) in percentage.

    Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation

  4. Change in functional class of angina by using CCS angina classification from baseline.

    Change in functional class of angina by using CCS angina classification will be summarized descriptively by visit

    Time frame: Before first dosing, and 1, 3, 6 , 12 months post cell transplantation

  5. Change in the 6-minute walk test (6-MWT) from baseline.

    The 6-MWT measures the distance walked on level ground in 6 minutes.

    Time frame: Before first dosing and 6, 12 months post cell transplantation

  6. Change in serum levels of amino-terminal pro-brain natriuretic peptide (NT pro-BNP) and high sensitivity cardiac troponin (hs-cTn) from baseline.

    Change in serum levels of NT pro-BNP and hs-cTn from baseline will be summarized descriptively.

    Time frame: Before first dosing, and 1, 3, 6 , 12 months post cell transplantation

  7. Change in quality of life using the Seattle Angina Questionnaire (SAQ) from baseline.

    The SAQ, a 19-item self-administered questionnaire measuring 5 dimensions of CAD: physical limitation, anginal stability, anginal frequency, treatment satisfaction and disease perception will be used to assess the functional change of CAD in HeXell-2020 administered patients.

    Time frame: Before first dosing, and 1, 3, 6 , 12 months post cell transplantation

  8. Change from baseline in echocardiographic measures.

    Myocardial performance \[including isovolumic relaxation time (IVRT), isovolumic contraction time (IVCT), LV ejection time (ET), and myocardial performance index (MPI or Tei Index)\]\[MPI= (IVCT+IVRT)/ET\]

    Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation

  9. Change in the evaluation result of CCTA from baseline

    Severity of stenosis assessed by 2022 Coronary Artery Disease Reporting and Data System (CAD-RADSTM 2.0), ranging from CAD-RADS 0 for absence of any plaque or stenosis to CAD-RADS 5 for the presence of at least 1 totally occluded coronary artery.

    Time frame: Before first dosing and at 3, 6 months post cell transplantation

  10. Change in the evaluation result of CCTA from baseline

    Coronary artery calcium score (CACS, as per Agatston method, J Am Coll Cardiol. 1990;15:827-32), higher scores mean a worse outcome.

    Time frame: Before first dosing and at 3, 6 months post cell transplantation

  11. Change from baseline in echocardiographic measures.

    Ventricular remodeling: LV end-diastolic volume (EDV) in mL, and end-systolic volume (ESV) in mL, stroke volume (SV in ), calculated by EDV - ESV ( mL)

    Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation.

  12. Change from baseline in echocardiographic measures.

    Ventricular remodeling: LV internal diameter in diastole and systole (LVIDd and LVIDs in mm), interventricular septum diameter (IVSD in mm), posterior wall thickness (PWT in mm), anteroseptal wall thickness (ASWT in mm)

    Time frame: Before first dosing and at 3, 6, 12 months post cell transplantation.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Dec 2025 → Aug 2026, primary completion Dec 2027 → Dec 2028 and completion Jul 2028 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Aug 22, 2025
StartActual
Aug 27, 2026was Dec 2025
Primary completionEst.
Dec 31, 2028was Dec 2027
CompletionEst.
Jul 31, 2029was Jul 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
1 site added — first site in Taiwan
Show site
  • Far Eastern Memorial Hospital · New Taipei City, Taiwan
Sep 29, 2026
Start date
Dec 1, 2025→Aug 27, 2026 (actual)
Sep 29, 2026
Primary completion
Dec 31, 2027→Dec 31, 2028
Sep 29, 2026
Study completion
Jul 31, 2028→Jul 31, 2029
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Taiwan
    Show site
    • Far Eastern Memorial Hospital · New Taipei City, Taiwan
    Start date Dec 1, 2025→Aug 27, 2026 (now actual)
    Primary completion Dec 31, 2027→Dec 31, 2028
    Study completion Jul 31, 2028→Jul 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07137104
Lead sponsor
Hexun Biosciences Co., LTD.
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 27, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Simon Huang, Dr.
Contact
simon.huang@hexunbio.com
+88633175088 ext. 6888
wannhsin chen, Dr.
Contact
whsin.chen@hexunbio.com
+88633175088 ext. 6688

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion